ABSTRACT

Objective  As the number of patients with COVID-19 increased, at-home care was introduced for the first time in South Korea. This study aimed to analyse the characteristics and outcomes of patients who were treated under at-home care.

Design, setting and participants  This retrospective cohort study targeted patients under at-home care for COVID-19 in Yeongdeungpo-gu in Seoul, Korea, from 18 October 2021 to 12 December 2021. The public health centre selected eligible patients for at-home care and registered with our institution. Nurses monitored patients, and doctors decided to transfer healthcare facilities and release the quarantined patients according to their symptoms.

Outcome measures  Patient characteristics during the course of at-home care.

Results  A total of 1422 patients were enrolled and 9574 patient-days were managed. Most patients were aged ≥60 years (22.7% (n=323)), and 82.8% did not have underlying conditions. The median length of care for patients was 8 days (IQR: 5–10 days). During the study period, 986 (69.3%) patients were released from quarantine, 82 (5.8%) patients were transferred to facilities and 354 (24.9%) patients were still under at-home care at the end of the study period. The most common cause of transfer was sustained fever (n=30; 36.6%), followed by dyspnoea and desaturation (n=17; 20.7%). Factors associated with transfer were diabetes (OR: 3.591, 95% CI 1.488 to 8.665, p=0.004), pregnancy (OR: 5.839, 95% CI 1.035 to 32.935, p=0.004), and desaturation (n=17; 20.7%). Factors associated with transfer were diabetes (OR: 3.591, 95% CI 1.488 to 8.665, p=0.004), pregnancy (OR: 5.839, 95% CI 1.035 to 32.935, p=0.004), and desaturation (n=17; 20.7%).

Conclusions  There were no specific problems related to patient safety when operating at-home care. Patients with risk factors, such as diabetes, were more likely to be transferred to healthcare facilities. For safe at-home care, it is necessary to prepare for an appropriate response to the emergency.

INTRODUCTION

SARS-CoV-2 was first discovered in Wuhan, China, in December 2019, and since the WHO announced the pandemic in March 2020, there have been approximately 290 million confirmed cases of COVID-19 worldwide, as of December 2021.1 2 With the development of vaccines, the number of confirmed cases in the USA and Europe seemed to be decreasing, but due to the easing of quarantine measures and the presentation of new variants, the number of confirmed cases skyrocketed again. There was no difference in the domestic situation. With the start of vaccination, the overall quarantine level was relieved. However, subsequently, a fourth epidemic occurred in Korea. In addition, emerging new variants have led to the updating of new confirmed cases daily.3

During each epidemic situation, the medical system faced a crisis, and it was accompanied by difficulties in allocating medical personnel, supplies and beds. During the initial epidemic, community treatment centres (CTC) for asymptomatic or mild patients were operated to fill the medical gap in Korea.4–6 As the epidemic progressed, it became difficult to cope with the increasing number of patients with COVID-19 with CTCs alone. The occurrence of paediatric and psychological problems was another challenge for the CTC setting.7 8

As the COVID-19 pandemic protracted, the Korean government modified its policy for the management of critically ill patients with COVID-19. The domestic metropolitan area introduced at-home care as an alternative to a deficient medical system. This is the first home healthcare system for the management and monitoring of patients suffering from infectious diseases in Korea. To overcome the current COVID-19 pandemic and prepare
for a novel infectious disease, a well-established at-home care system is required. In this study, we aimed to introduce an at-home care protocol that is being implemented through our institution and analyse the characteristics and outcomes of patients under at-home care during the COVID-19 pandemic.

MATERIALS AND METHODS
Study design, setting and study population
This was a retrospective cohort study that used medical records. Kangnam Sacred Heart Hospital is a secondary university hospital with 572 beds located in Yeongdeungpo-gu, Seoul, South Korea. This institution provides internal medicine, surgery and paediatric intensive care units, as well as an emergency centre and outpatient department. This institution is responsible for treating patients mainly in the local constituency. Our institution signed an agreement with Yeongdeunpo-gu administration to become a provider of at-home medical care on 5 October 2021 and started operating as such on 18 October 2021. All patients under at-home care via Kangnam Sacred Heart Hospital between 18 October 2021 and 12 December 2021 were included in this study.

Criteria for patient enrolment and release from quarantine
In Korea, COVID-19 was designated as a class 1 legal infectious disease, which required all confirmed patients to report to public health authorities and to be quarantined for a set period. The person in charge of the public health centre interviewed all patients with confirmed diagnoses of COVID-19 and determined whether at-home care was appropriate or if they required hospital admission. Patients who could be treated at home and who provided consent to public health centre were registered at our institution as at-home care patients.

On 26 November 2021, policies for the care of patients with COVID-19 were changed, as were the criteria for at-home care. Before this date, asymptomatic patients with confirmed COVID-19 and those with mild symptoms under 70 years of age with no risk of hospitalisation were eligible to receive at-home care. From 26 November 2021 onwards, all patients were eligible to receive at-home care and were admitted to healthcare facilities only if there was a need for hospitalisation.

Enrolment criteria
Before 26 November 2021, the Korea Centers for Disease Control and Prevention classified patients with asymptomatic and mild symptoms under 70 years of age as candidates for at-home care, following consent, except in the presence of the following risk factors for hospitalisation: mental change after symptom onset of COVID-19, dyspnoea, uncontrolled fever with antipyretics, uncontrolled diabetes mellitus (DM), haemodialysis, patients treated for chronic lung disease, asthma, heart failure, coronary artery disease, patients under chemotherapy or immunosuppressant, uncontrolled symptomatic psychiatric disease, bedridden states, obese (body mass index >30 kg/m²), pregnant women with symptoms, such as abdominal pain, labour, vaginal bleeding, childhood who was with a high risk of dyspnoea, cyanosis, chest depression, poor oral intake or dehydration, diagnosed with chronic lung disease/cardiac disease/metabolic disease/abnormal immune system, under immunosuppressant, respiratory function or excretion problem, or risk of aspiration. Among patients over 60 years of age, only those who had been vaccinated were registered for at-home care. Patients in need of care, such as minors and those with disabilities, were required to be accompanied by a caregiver. The exclusion criteria were as follows: (1) those who lived in a residential environment vulnerable to infection due to difficulty in distancing or (2) when communication for non-face-to-face healthcare and quarantine management was difficult for the patient or caregiver.

From 26 November 2021, patients with a confirmed COVID-19 diagnosis were all allocated to at-home care, except in the following cases: (1) those who had the aforementioned risk factors for hospitalisation, (2) those who lived in a residential environment vulnerable to infection, (3) individuals who were minors, disabled or over the age of 70 years who required care but could not be quarantined together with a caregiver, and (4) those who were deemed ineligible for at-home care treatment by the local government head (eg, due to a legal problem, etc).

Criteria for release from quarantine
Symptomatic patients were released from quarantine 10 days after symptom onset. Asymptomatic patients were released from quarantine 10 days after diagnosis. The quarantine date was extended depending on the occurrence of symptoms, and the final decision for release was made by the medical staff.

Intervention
Kangnam Sacred Heart Hospital operated at-home care by targeting patients with COVID-19 residing in Yeongdeungpo-gu. The at-home care programme involved four medical doctors and five nurses in one monitoring room. They operated during the day and used an on-call system at night. One doctor was in charge per day, but a backup doctor was designated in case of an emergency. Nurses worked in two shifts, with two nurses during the daytime and evening and one during the night for the on-call system.

The Yeongdeungpo-gu public health centre classified patients with COVID-19 for at-home care according to the enrolment criteria and supplied items necessary for at-home care, such as antipyretics, an oxygen saturation monitor, a thermometer and phone numbers of related medical institutions. The patients to be managed were registered as outpatients with assigned doctors every day so that prescriptions were available if needed. The list of patients under at-home care was secured through the public health centre and updated daily.
The monitoring room was equipped with computers, monitors and smartphones. Patients checked their blood pressure and body temperature and uploaded the data via smartphone applications. Nurses called the patient at 09:00 and 17:00 daily to check the patient’s vital signs and symptoms and update patient information on electronic health records. If the patient had symptoms and wanted to take medication, the doctor interviewed the patient and prescribed the medicine. The prescription was sent to the public health centre by fax. After prescribing the medicine at the pharmacy, the person in charge of the public health centre delivered the medicine to the patient’s house. If the patient had persistent fever, desaturation or worsening clinical symptoms, the doctor interviewed the patient and decided whether to transfer the patient to another facility at the discretion of that doctor, such as a CTC or hospital, according to severity. The public health centre assigned an ambulance and medical institution and transported the patient accordingly.

The medical staff checked the list of patients who were subject to release from quarantine daily and assessed whether it was possible to release them from quarantine according to the criteria. When those under quarantine were released, at-home care and monitoring also ended. The results were then reported to the public health centre.

**Data collection and statistical analysis**

Data regarding patient characteristics, such as age, sex, enrolment date, release from quarantine date, transfer date (if transferred), symptoms and medical prescription, were collected through a retrospective medical record review.

Continuous variables are presented as mean±SD or median (IQR), as appropriate. Statistical significance was assessed using the χ² test and Fisher’s exact test for categorical variables. Non-categorical variables were tested using the two-sided unpaired t-test or Mann-Whitney U test. The factors associated with transfer were calculated using a logistic regression model. Statistical significance was set at p<0.05. All statistical analyses were performed using SPSS V.27 (IBM).

**RESULTS**

**Baseline characteristics of study population**

During the study period, 1453 patients were registered. Three patients moved to another district, and 28 patients were excluded from at-home care on the day of admission due to other causes of admission, such as severe symptoms at diagnosis. Finally, a total of 1422 patients and 9574 patient-days were managed under at-home care at Kangnam Sacred Heart Hospital. The number of patients managed daily is shown in figure 1.

Among the 1422 patients, 725 (51.0%) were male, and the median age was 40 (IQR: 27–58, range: 0–87) years (table 1). Most patients were over 60 years of age (22.7% (n=323)), followed by those in their 30s (18.5% (n=263)). Further, most patients (n=1177; 82.8%) did not have underlying conditions, and hypertension (n=153; 10.8%)
was the most common comorbidity. Approximately 16.4\% (n=233) of patients under at-home care were asymptomatic. There were 209 cases of drug prescriptions in 176 (12.4\%) patients. On average, 3.7±3.73 (range: 0–16) prescriptions were requested per day. Symptoms for the prescribed drugs are described in table 2. The most common symptom was cough (n=115; 55.8\%), followed by sputum production (n=62; 30.1\%) and sore throat (n=54; 26.2\%). Night calls occurred in 68 cases which was an average of 1.2±1.64 (range: 0–6 cases) night calls per day.

The median length from symptoms to diagnosis was 2 days (IQR: 1–4 days), and 1 day (IQR: 0–1 day) from diagnosis to management. The median length of care for

| Characteristics                      | Total (n=1422) | Released from quarantine (n=986) | Transferred (n=82) | P value |
|--------------------------------------|---------------|---------------------------------|--------------------|---------|
|                                      | n (%)         | n (%)                           | n (%)             |         |
| Sex                                  |               |                                 |                    |         |
| Male                                 | 725 (51.0)    | 508 (51.5)                      | 43 (52.4)          | 0.873   |
| Female                               | 697 (49.0)    | 478 (48.5)                      | 39 (47.6)          |         |
| Mean age, years (range)              | 40 (0–87)     | 40 (0–83)                       | 45 (1–87)          | 0.051   |
|                                      | 156 (11.0)    | 109 (11.1)                      | 3 (3.7)            |         |
| 10–19                                | 122 (8.6)     | 73 (7.4)                        | 10 (12.2)          |         |
| 20–29                                | 151 (10.6)    | 112 (11.4)                      | 8 (9.8)            |         |
| 30–39                                | 263 (18.5)    | 194 (19.7)                      | 14 (17.1)          |         |
| 40–49                                | 186 (13.1)    | 120 (12.2)                      | 11 (13.4)          |         |
| 50–59                                | 221 (15.5)    | 152 (15.4)                      | 11 (13.4)          |         |
| ≥60                                  | 323 (22.7)    | 225 (22.9)                      | 25 (30.5)          |         |
| Underlying conditions                |               |                                 |                    |         |
| Hypertension                         | 153 (10.8)    | 99 (10.0)                       | 15 (18.3)          | 0.020   |
| Diabetes                             | 43 (3.0)      | 28 (2.8)                        | 7 (8.5)            | 0.005   |
| Thyroid disease                      | 22 (1.5)      | 17 (1.7)                        | 0 (0)              | 0.231   |
| Psychiatric disorder                 | 12 (0.8)      | 10 (1.0)                        | 1 (1.2)            | 0.860   |
| Pregnancy                            | 6 (0.4)       | 4 (0.4)                         | 2 (2.4)            | 0.018   |
| Others*                              | 53 (3.7)      | 26 (2.6)                        | 5 (6.1)            |         |
| None                                 | 1177 (82.8)   | 820 (83.2)                      | 60 (73.2)          | 0.022   |
| Symptoms                             |               |                                 |                    | 0.009   |
| Asymptomatic                         | 233 (16.4)    | 159 (16.1)                      | 7 (8.5)            |         |
| Presymptomatic                       | 160 (11.3)    | 89 (9.0)                        | 15 (18.3)          |         |
| Symptomatic                          | 1029 (72.4)   | 738 (74.8)                      | 60 (73.2)          |         |
| Medicine prescription                | 176 (12.4)    | 117 (11.9)                      | 21 (25.6)          | 0.020   |
| Transfer to healthcare facilities    | 82 (5.8)      | 54.9                            | 95.1               |         |
|                                      |               |                                 | 14 days            |         |
|                                      |               | 74.4                            | 95.1               |         |
|                                      |               | 100                             | 100                |         |
|                                      |               |                                 |                    |         |
| Cumulative percentage of duration from symptom onset to transfer (%) | | | | |
| 3 days                               | 18.3          |                                 |                    |         |
| 5 days                               | 54.9          |                                 |                    |         |
| 7 days                               | 74.4          |                                 |                    |         |
| 10 days                              | 95.1          |                                 |                    |         |
| 14 days                              | 100           |                                 |                    |         |
|                                      |               |                                 |                    |         |
| Median days from symptoms to diagnosis, days (IQR) | 2 (1–4) | 2 (1–4) | 2 (1–3.75) | 0.307 |
| Median days from diagnosis to management, days (IQR) | 1 (0–1) | 1 (0–2) | 0 (0–1) | <0.001 |
| Median management days†, days (IQR) | 8 (5–10) | 8 (6–10) | 3 (2–4.25) | <0.001 |

*Epilepsy, autoimmune disease, liver disease, asthma, bronchiectasis, angina, cerebrovascular disease, ulcerative colitis.
†Released from quarantine and transferred patients, excluded under management.
patients was 8 days (IQR: 5–10 days). During the study period, 986 (69.3%) patients were released from quarantine, 82 (5.8%) patients were transferred to CTCs or hospitals and 354 (24.9%) patients were still under at-home care when the study period ended. No patients under at-home care died during the study period.

Characteristics according to transfer

A total of 82 (5.8%) patients were transferred. Sex and age did not differ significantly according to the transfer (table 1). Among the transferred patients, 52.4% (n=43) were male, and patients over 60 years of age (n=25; 30.5%) were most frequently transferred. Patients with comorbidities were significantly more likely to be transferred than those who were released from quarantine (25.8% vs 16.8%, p=0.022). The proportion of patients with hypertension and DM was significantly higher among transferred patients (10.0% vs 18.3%, p=0.020; 2.8% vs 8.5%, p=0.005). The proportion of pregnant women was significantly higher among transferred patients (0.4% vs 2.4%, p=0.018). The median management duration of at-home care was 8 days (IQR: 6–10 days) for release from quarantine and 3 days (IQR: 2–4.25 days) for transferred patients.

The most common cause of transfer was sustained fever (n=30; 36.6%) (table 3). Seventeen patients (20.7%) were transferred because of dyspnoea, and their oxygen saturation was <90%. The time from symptom onset to transfer request was a median of 5 days (IQR: 4–8 days), and a median of 3 days (IQR: 2–5 days) was required from diagnosis to transfer request. Most transfers (n=61; 75.5%) were made on the same day as the transfer requests. For 21 (25.6%) patients, it took 1 day to allocate a bed after the request. One patient required 2 days and one patient required 3 days for transfer. All patients with dyspnoea were transferred on the same day.

### Table 2

| Symptoms                  | n (%)  |
|---------------------------|--------|
| Cough                     | 115 (55.8) |
| Sputum production         | 62 (30.1)  |
| Sore throat               | 54 (26.2)  |
| Nasal congestion          | 38 (18.4)  |
| Rhinorrhoea               | 33 (16.0)  |
| Fever                     | 17 (8.3)   |
| Headache                  | 14 (6.8)   |
| Myalgia                   | 8 (3.9)    |
| Conjunctivitis            | 7 (3.4)    |
| Gastrointestinal symptoms | 7 (3.4)    |
| Other†                    | 10 (4.9)   |

*Allowed duplicates.
†Sleep disorder, febrile sense, underlying disease.

### Table 3

| Reasons                              | n (%)  |
|--------------------------------------|--------|
| Sustained fever                      | 30 (36.6) |
| Dyspnoea/desaturation                | 17 (20.7) |
| Patients wanted                      | 13 (15.9) |
| Cough/chest pain                     | 9 (11.0)   |
| Resident with family                 | 5 (6.1)    |
| Minor                                | 4 (4.9)    |
| Aggravation of underlying disease    | 2 (2.4)    |
| As caregiver                         | 1 (1.2)    |
| Old age                              | 1 (1.2)    |

### Risk factors for transfer

The factors associated with transfer are shown in table 4. In univariate analysis, age and sex were not significantly associated with transfer. The presence of underlying disease (OR: 1.811, 95% CI 1.081 to 3.035, p=0.024), hypertension (OR: 2.006, 95% CI 1.104 to 3.644, p=0.022), DM (OR: 3.193, 95% CI 1.350 to 7.553, p=0.008) and pregnancy (OR: 6.137, 95% CI 1.107 to 34.023, p=0.038) was significantly associated with transfer. On multivariate analysis, we found no significant association of age or sex with transfer. DM (OR: 3.591, 95% CI 1.488 to 8.665, p=0.004), pregnancy (OR: 5.839, 95% CI 1.035 to 32.935, p=0.046) and being presymptomatic (OR: 4.015, 95% CI 1.559 to 10.337, p=0.004) were independent risk factors for transfer.

### DISCUSSION

Despite the increase in vaccination against COVID-19, the number of confirmed cases worldwide has been increasing due to the easing of quarantine measures, waning vaccination immunity and the emergence of new SARS-CoV-2 variants. Because of the limitations of medical manpower and resources, such as hospital beds, at-home care was introduced in Korea. As this system was introduced for the first time in Korea, we aimed to explain the initial operating protocol and results.

In Korea, since the first COVID-19 outbreak in Daegu in 2020, CTCs have been operating in the face of the COVID-19 epidemic. Some facilities, such as dormitories and hotels, were converted to quarantine units for patients with COVID-19, and a monitoring system for patients with stationed medical staff was established. This system was flexibly operated according to trends in the number of confirmed cases. To operate a CTC, it is necessary to provide a space for both quarantining patients and working medical staff. To prepare such facilities, a certain period was required, and after the increase in the number of confirmed cases, there were difficulties in arranging space and medical staff. This could be managed in the case of a short-term epidemic, but as the epidemic became longer and the number of confirmed cases increased, like during the fourth epidemic in Korea, there was a limit
Open access

to the management through CTCs. The medical system was saturated due to the number of confirmed cases and the increase in the number of patients with severe cases; therefore, the government of the Republic of Korea changed the policy for the management of severely ill patients. As a result, at-home care was introduced in Korea. Before the fourth epidemic, some local governments operated at-home care by a public health centre for certain patients, such as children and their parents, or patients who were healthy and young. As the fourth epidemic began, at-home care expanded its target to all over the country and was managed by hospitals from October 2021.

With the COVID-19 pandemic, some countries, including the USA, quarantined asymptomatic or mild patients in their homes without hospitalisation.11–14 At-home care in Korea was a system that monitored patients twice a day over the phone. Procurement of necessary supplies and transfer systems were established and managed. Through this system, some solutions have been suggested for medical problems that could be missed due to simple home quarantine alone.

Entering quarantine facilities, such as a CTC, due to COVID-19 could cause psychological problems. Approximately 30% of patients admitted to a CTC presented with psychological problems due to quarantine in an unfamiliar environment.8 In particular, when considering psychological factors and diagnosis time after symptom onset in paediatric patients, which might be after the transmission period had passed, quarantine in a CTC or hospital was somewhat disadvantageous.7 At-home care compensated for the psychological disadvantages of CTCs by maintaining quarantine in a familiar environment, especially with family.

Respiratory symptoms, such as cough, sputum production, sore throat, fever and anosmia, were symptoms of COVID-19.13–15 In the present study, cough was the most common symptom for which medicines were prescribed. Most prescribed medicines were for respiratory symptoms, but there were also cases of digestive symptoms, conjunctivitis or sleep disorder. As the COVID-19 epidemic persisted and many patients were treated under at-home care, strategic preparedness was required so that medicines for respiratory symptoms and other possible symptoms could be smoothly supplied to patients. In some cases, patients ran out of medications that were being taken in cases of underlying conditions. This indicated that, during the quarantine period, there may be a need for an alternative to the prescription of medicines for underlying conditions, such as hypertension.

Elderly patients and pregnant women have a high risk of acute exacerbation and severity.16–18 Comorbidities, such as hypertension and DM, were other risk factors for disease aggravation in patients with COVID-19.18 In the present study, DM and pregnancy were risk factors for transfer, along with presymptomatic status. Although age was not significantly associated with transfer, 30.5% of transferred patients were older than 60 years. At-home care patients with underlying conditions or old age required more thorough management with caution.

In the present study, 5.8% of patients were transferred to CTCs or hospitals. In a previous study of CTCs that treated asymptomatic or mild patients with COVID-19, the transfer rate ranged from 0.7% to 10.3%.16,19,20

| Variables               | Univariate analysis | Multivariate analysis |
|-------------------------|---------------------|----------------------|
|                        | OR      | 95% CI     | P value | OR      | 95% CI     | P value |
| Female sex              | 0.964   | 0.614 to 1.513 | 0.873   | 0.742   | 0.579 to 1.476 | 0.742   |
| Age (years)             |         |           |         |         |           |         |
| 0–9                     | 0.385   | 0.100 to 1.491 | 0.167   | 0.439   | 0.112 to 1.723 | 0.238   |
| 10–19                   | 1.918   | 0.723 to 5.086 | 0.191   | 2.169   | 0.804 to 5.849 | 0.126   |
| 20–29                   | Reference | Reference | Reference | Reference | Reference | Reference |
| 30–39                   | 0.982   | 0.411 to 2.483 | 0.982   | 0.957   | 0.384 to 2.386 | 0.924   |
| 40–49                   | 0.605   | 0.498 to 3.306 | 0.605   | 1.371   | 0.523 to 3.596 | 0.521   |
| 50–59                   | 0.978   | 0.395 to 2.601 | 0.978   | 0.961   | 0.360 to 2.566 | 0.937   |
| >60                     | 0.300   | 0.677 to 3.544 | 0.300   | 1.346   | 0.547 to 3.315 | 0.518   |
| Underlying disease      | 1.811   | 1.081 to 3.035 | 0.024   | 0.662   | 0.219 to 1.999 | 0.465   |
| Hypertension            | 2.006   | 1.104 to 3.644 | 0.022   | 2.106   | 0.682 to 10.208 | 0.196   |
| Diabetes mellitus       | 3.193   | 1.350 to 7.553 | 0.008   | 3.591   | 1.488 to 8.665 | 0.004   |
| Pregnancy               | 6.137   | 1.107 to 34.023 | 0.038   | 5.839   | 1.035 to 32.935 | 0.046   |
| Symptoms                |         |           |         |         |           |         |
| Asymptomatic            | Reference | Reference | Reference | Reference | Reference | Reference |
| Presymptomatic          | 3.828   | 1.505 to 9.741 | 0.005   | 4.015   | 1.559 to 10.337 | 0.004   |
| Symptomatic             | 1.847   | 0.829 to 4.115 | 0.134   | 1.983   | 0.880 to 4.469 | 0.099   |

Table 4 Factors associated with transfer
Patients transferred for worsening of symptoms requested a transfer at a median of 5 days after symptom onset and a median of 3 days from diagnosis. The duration from diagnosis to transfer was different on comparison with a previous study reporting a median of 3.5–11 days. As COVID-19 was reported that symptoms were aggravated between 4 and 14 days after symptom onset. However, in the remaining 45%, symptoms worsened 6 days after symptom onset. Some studies reported that symptoms were aggravated between 4 and 14 days after symptom onset. As COVID-19 epidemic prolonged, the monitoring period of at-home care was changed from 10 to 7 days, and the remaining 3 days were either monitored or not depending on symptoms. Patients with risk factors were monitored thoroughly, as there were some patients who needed to be transferred to a CTC or hospital even at the end of monitoring.

This system was not a monitoring and treatment system that checks a patient in real time. The worsening of symptoms may have been missed. This risk was even greater in patients who received at-home care alone. In addition, if the patient did not feel any symptoms even when the condition worsened, the patient might have been left unattended. Difficulty in responding to emergent situations was another problem. Since the patient was not treated in the same space as medical personnel, it took time to directly contact the medical personnel, even if the symptoms were monitored. In addition, after confirming the transfer, it took time to assign and implement emergency measures. Unlike in a CTC, if a transfer was delayed, proper medical measures, such as oxygen supply, were also delayed, which could prove to be fatal to patients. Therefore, there is a need for a system that secures and uses an ambulance and an available emergency bed for at-home care patients in advance.

Currently, in a situation where the number of patients with COVID-19 has skyrocketed and the basic treatment policy has been switched to at-home care, the number of patients receiving at-home care is continuously increasing. Because at-home care was a system in which medical staff directly interviewed patients twice a day over the phone, medical personnel were needed for this. Administrative personnel were also required to allocate patients, deliver supplies and deliver drugs through prescriptions. In the beginning of the COVID-19 epidemic, patient management with the help of assigned medical personnel was possible, but as the number of patients increased, management by the existing staff became difficult. This may lead to future difficulties in identifying patients and responding to patients. In preparing for the continuing epidemic, measures should be taken on how to procure the required manpower.

This study had some limitations. First, this was a single-centre study. As at-home care has been expanded to cover the entire nation and all patients confirmed to have COVID-19, it is necessary to analyse additional data of the results of at-home care. Second, this study analysed the results of the early phase of at-home care, which was a point in time when the setting was not completely established. Thus, additional system supplementation is required.

CONCLUSION
Due to the increase in the number of confirmed cases beyond those that medical facilities could handle, at-home care was an unavoidable option. Patients with risk factors, such as DM, were more likely to be transferred to healthcare facilities. For safe at-home care, it is necessary to prepare for an appropriate response to the emergency.

Contributors YBS conceptualised and edited the manuscript. JJP contributed to data curation, data analysis and manuscript writing. JL, SHN and YKC contributed to acquisition of data. All authors have read and approved the submission. YBS acts as a guarantor for the manuscript.

Funding This study was supported by the Korea National Research Foundation (NRF) grant funded by the Korean government (Ministry of Education, Science and Technology) (NRF-2021-M3E5E308120711).

Competing interests None declared.

Patient and public involvement Patients and/or the public were not involved in the design, conduct, or reporting, or dissemination plans of this research.

Patient consent for publication Not required.

Ethics approval The study was approved by the Institutional Review Board (IRB) of Kangnam Sacred Heart Hospital (IRB No: 2021-11-035-001), and the requirement for informed consent was waived.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement Data are available upon reasonable request. No data are available.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

ORCID iD
Yu Bin Seo http://orcid.org/0000-0001-5183-1996

REFERENCES
1 World Health Organization. Coronavirus (COVID-19) dashboard, 2021. Available: https://covid19.who.int [Accessed 01 Jan 2022].
2 World Health Organization (WHO). Timeline: WHO's COVID-19 response, 2021. Available: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/interactive-timeline [Accessed 01 Jan 2022].
3 Korea Disease Control and Prevention Agency. Coronavirus disease-19 (COVID-19) (in Korean), 2022. Available: http://ncov.mohw.go.kr/ [Accessed 15 Jan 2022].
4 Choi WS, Kim HS, Kim B, et al. Community treatment centers for isolation of asymptomatic and mildly symptomatic patients with coronavirus disease, South Korea. Emerg Infect Dis 2020;26:2338–45.
5 Kang E, Lee SY, Jung H, et al. Operating protocols of a community treatment center for isolation of patients with coronavirus disease, South Korea. Emerg Infect Dis 2020;26:2329–37.
6. Lee SY, Song KJ, Lim CS, et al. Operation and management of Seoul metropolitan city community treatment center for mild condition COVID-19 patients. *J Korean Med Sci* 2020;35:e367.

7. Yun KW, Kim KM, Kim YK, et al. Limited benefit of facility isolation and the rationale for home care in children with mild COVID-19. *J Korean Med Sci* 2021;36:e45.

8. Kang E, Lee SY, Kim MS, et al. The psychological burden of COVID-19 stigma: evaluation of the mental health of isolated mild condition COVID-19 patients. *J Korean Med Sci* 2021;36:e33.

9. Korea Disease Control and Prevention Agency. *Coronavirus Disease-19 at-home care guide*. 4th ed. in Korean, 2021. https://www.kdca.go.kr/board/board.es?mid=a20507020000&bid=0019&act=view&list_no=717487

10. Korea Disease Control and Prevention Agency. *Coronavirus Disease-19 at-home care guide*. 5th ed. in Korean, 2021. https://www.kdca.go.kr/board/board.es?mid=a20507020000&bid=0019&act=view&list_no=717950

11. Wang T-Y, Liu H-L, Lin C-Y, et al. Emerging success against the COVID-19 pandemic: hospital surge capacity in Taiwan. *Ann Emerg Med* 2020;76:374–6.

12. Wilder-Smith A, Chiew CJ, Lee VJ. Can we contain the COVID-19 outbreak with the same measures as for SARS? *Lancet Infect Dis* 2020;20:e102–7.

13. Centers for Disease Control and Prevention. Interim guidance for implementing home care of people not requiring hospitalization for coronavirus disease 2019 (COVID-19), 2020. Available: https://www.cdc.gov/coronavirus/2019-ncov/hcp/guidance-home-care.html [Accessed 03 Jan 2022].

14. Ministry of Health – Singapore. Eligible for home recovery programme, 2021. Available: https://www.covid.gov.sg/unwell/hrp

15. Park PG, Kim CH, Heo Y, et al. Out-of-hospital cohort treatment of coronavirus disease 2019 patients with mild symptoms in Korea: an experience from a single community treatment center. *J Korean Med Sci* 2020;35:e140.

16. Booth A, Reed AB, Ponzo S, et al. Population risk factors for severe disease and mortality in COVID-19: a global systematic review and meta-analysis. *PloS One* 2021;16:e0247461.

17. Geng M-J, Wang L-P, Ren X, et al. Risk factors for developing severe COVID-19 in China: an analysis of disease surveillance data. *Infect Dis Poverty* 2021;10:48.

18. Tang Q, Liu Y, Fu Y, et al. A comprehensive evaluation of early potential risk factors for disease aggravation in patients with COVID-19. *Sci Rep* 2021;11:8062.

19. Lee Y-H, Hong CM, Kim DH, et al. Clinical course of asymptomatic and mildly symptomatic patients with coronavirus disease admitted to community treatment centers, South Korea. *Emerg Infect Dis* 2020;26:2346–52.

20. Choi MH, Ahn H, Ryu HS, et al. Clinical characteristics and disease progression in early-stage COVID-19 patients in South Korea. *J Clin Med* 2020;9:1959.

21. Cohen PA, Hall LE, John JN, et al. The early natural history of SARS-CoV-2 infection: clinical observations from an urban, ambulatory COVID-19 clinic. *Mayo Clin Proc* 2020;95:1124–6.

22. Boban M. Novel coronavirus disease (COVID-19) update on epidemiology, pathogenicity, clinical course and treatments. *Int J Clin Pract* 2021;75:e13868.